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with penumococci, several boundaries and weaknesses in modeling occur: only steady 
state analysis possible; no dynamic implementation of herd immunity and replacement 
effects; and no inﬂuence of changing demographic structure over time Therefore a 
comparable ODE system was implemented and extended by population dynamics and 
splitting the pneumococcal serotypes in groups depending on their behavior depending 
on immunization. RESULTS: For standard immunization program implementation as 
advocated by EPAR/EMEA it was possible to reproduce the behaviour of the Markov-
ian-Model with the ODE approach resulting in equivalent outcomes for validation.
Using ODE approach extensions the inﬂuence of population dynamic effects with and 
without immunization is compared in detail. Using the mathematical theory for ODEs 
stability and uniqueness of the implemented approach was shown. CONCLUSIONS: 
The Markovian model can accurately describe the infection with pneumococcal bac-
teria if proper data exists and if there is no need to use dynamic effects or feedback-
loops. The ODE model offers possibilities to implement additional dynamic methods, 
which is essential to gather the real world dynamics.
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OBJECTIVES: The aim of this project is to generate an assessment for the new pneu-             
mococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-
CV) in Italy. Currently, pneumococcal vaccination is not recommended nationally,          
but many regions adopted 7-valent pneumococcal (PCV-7) vaccination.    METHODS: 
The project was performed using the Health Technology Assessment (HTA) methodol-
ogy with a large input of multidisciplinary panel of experts with different backgrounds 
such as clinicians, epidemiologists and health economists. RESULTS: Literature and  
national database review revealed at least 300 pneumococcal meningitis and 4.000 
pneumococcal bacteremia cases per year in Italy. The additional pneumococcal sero-
types (ST) included in PHiD-CV (ST1, 5 and 7F) account for at least 10% of all 
Invasive Pneumococcal Disease (IPD) cases. The amount of pneumococcal and NTHi 
pneumonia cases was estimated at around 70.000 cases per year. More than one 
million infant episodes of otitis media (OM) are reported annually. Around 50% of 
these cases are caused by two bacteria, Streptococcus pneumonia and NTHi. The total 
annual direct medical cost related to pneumococcal and NTHi disease could exceed 
110 million Euros in Italy. Modelling the impact of PHiD-CV vaccine with a cohort 
model populated with Italian data shows a huge health gain in IPD, pneumonia and 
OM. The new vaccine demonstrates superior clinical results and important cost-offsets 
compared with no vaccination. It dominates as well the current vaccination option of 
PCV-7, leading to signiﬁcant cost savings. CONCLUSIONS: Pneumococcal vaccina-
tion emerges as an important public health improvement in Italy; at the same price, 
PHiD-CV appears the preferable choice for routine child immunization programs.
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OBJECTIVES: Gout patients in the Department of Veterans Affairs (VA) are often 
difﬁcult to manage (DTM) with multiple co-morbidities (diabetes, hypertension, renal 
disease) that are associated with cardiovascular thrombotic events (CVTE) and other 
cardiac events (OCE). Our objectives were to describe rates of CVTE and OCE among 
patients with gout and to determine if increased CVTE or OCE occurred in patients 
with DTM gout. METHODS: We used VA national databases to select all patients 
with gout diagnoses (ICD-9  274.xx) in an index year of 2004 with follow-up 
through 2006. We identiﬁed patients with ICD-9 codes for OCEs and CVTE diagno-
ses, based upon deﬁnitions from the Antiplatelet Trialists’ Collaboration. ICD-9 codes 
for gout nephropathy or tophi were used to identify DTM patients. We calculated 
odds ratios with 95% conﬁdence intervals (OR, CI) to compare risk of CVTE, OCE, 
and mortality among DTM versus other gout patients. RESULTS: Of 156,809 VA 
gout patients, 2534 (1.6%) had CVTE and 9759 (6.2%) had OCE in 2004. Rates 
were similar for 2005 and 2006: 1.6% and 1.3% for CVTE, 6.2% and 5.7% for 
OCE. DTM patients, deﬁned as having diagnostic codes of gout nephropathy (ICD-9 
of 274.1x, n  1667) and/or tophi (ICD-9 of 274.8x, n  1780), had similar rates of 
CVTE as other gout patients in 2004 (1.9% vs. 1.6%, OR  1.16, CI  0.90–1.50), 
but increased risk in 2005 (2.2% vs. 1.5%, OR  1.41, CI  1.13–1.77) and 2006 
(2.0% vs. 1.3%, OR  1.54, CI  1.23–1.93). OCEs were signiﬁcantly greater each 
year in DTM gout patients; 2004: 9.9% vs. 7.6%, OR  1.33, CI  1.19–1.50; 2005: 
11.1% vs. 7.4%, OR  1.57, CI  1.41–1.74; 2006: 11.3% vs. 6.8%, OR  1.75, CI 
 1.58–1.94. Mortality was signiﬁcantly greater in DTM gout patients; 2004: 3.3% 
vs. 4.0%, OR  1.21, CI  1.01–1.44; 2005: 3.3% vs. 4.8%, OR  1.49, CI  1.28–
1.73; 2006: 3.2% vs. 4.6%, OR  1.49, CI  1.27–1.73. CONCLUSIONS: Patients 
with DTM gout have greater risks for CVTEs, OCEs, and mortality.
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OBJECTIVES: Comparison of leﬂunomide, methotrexate and sulfasalazine safety 
based on data from WHO Programme for International Drug Monitoring. METHODS: 
The data from countries participating in the World Health Organization Programme 
for International Drug Monitoring are collected and maintained, on behalf of the 
WHO, by the Uppsala Monitoring Centre, in the Vigibase. An analysis of data on 
adverse events (AE) of leﬂunomide, methotrexate and sulfasalazine reported to Vigi-
base since 2000 up to 16th March 2009 (ref: ER18-2009), was performed. RESULTS: 
The total number of 16,311 individual case reports of leﬂunomide adverse events were 
registered in the Vigibase, compared to 32,945 and 5,011 for methotrexate and sul-
fasalazine, respectively. There were 108 death cases registered for leﬂunomide, 236 
for methotrexate and 18 for sulfasalazine. Most frequent system-organ classes reported 
were: gastro-intestinal system disorders (13.2%) and skin and appendages disorders 
(9,8%) for leﬂunomide, respiratory system disorders (11.6%) and general disorders 
(10.8%) for methotrexate and skin and appendages disorders (17.7%) and general 
disorders (14.6%) for sulfasalazine. Most frequent AE reports for leﬂunomide were: 
diarrhoea (588 cases versus 303 and 58 for methotrexate and sulfasalazine, respec-
tively), dyspnoea (310 vs. 563 vs. 53), hepatic function abnormal (304 vs. 262 vs. 78), 
nausea (272 vs. 401 vs. 90), rash (270 vs. 181 vs. 209), hypertension (265 vs. 138 vs. 
6) and anaemia (242 vs. 383 vs. 55). Congenital abnormalities were reported in 26 
leﬂunomide, 204 methotrexate and 15 sulfasalazine patients. CONCLUSIONS: WHO 
data indicates that leﬂunomide is at least as safe as methotrexate. All three disease 
modifying drugs have different spectrum of adverse events.
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OBJECTIVES: The primary objective was to estimate the proportion of patients suf-
fering from osteoporosis among postmenopausal women who could beneﬁt from 
therapeutic recommendations according to the French guidelines after performing a 
BMD diagnosis measurement. METHODS: Cross sectional observational study was 
performed of postmenopausal women, not treated for osteoporosis for at least one 
year and who could beneﬁt from therapeutic recommendations according to the 
French guidelines after performing a BMD. RESULTS: A total of 647 postmenopausal 
women were enrolled (646 analyzed) by 78 rheumatologists performing BMD mea-
surement between May 2007 and January 2008. The BMD measurement were pre-
scribed by rheumatologists (42.6%), GPs (34.1%), Ob/Gynecologist (18.1%) or other 
physicians (5.1%). The mean age was 66 o 9 years. According to the WHO deﬁnition, 
densitometry osteoporosis diagnosis was made in 57.6% patients (IC95% 53.7; 61.4), 
osteopenia diagnosis in 38.7% patients (IC95% 34.9; 42.6); and a normal BMD was 
established in 3.7% patients. A total of 39.7% of patients had at least a prevalent 
fracture and a treatment other than calcium and vitamin D supplementation was rec-
ommended in 93.0% cases of osteoporosis, in 44.8% in case of osteopenia and 8.3% 
in case of normal BMD. In a logistic regression model, the factors inﬂuencing thera-
peutic decision making in this population were the osteoporosis diagnosis versus 
osteopenia diagnosis OR  21.0 (IC95% 12.5; 35.3), past or current glucocorticoids 
use OR  2.7 (IC95% 1.3; 5.7). The fracture type was also important in decision making; 
existing vertebral fracture versus none OR  17.2 (IC95% 5.8; 51.4), existing non ver-
tebral fracture versus none OR  4.7 (IC95% 2.7; 8.4). CONCLUSIONS: In a real 
setting, osteoporosis was diagnosed in approximately 60% of the women who under-
went a BMD diagnosis and who complied with the French therapeutic guidelines. 
Therapeutic recommendations decision making was inﬂuenced mainly by BMD 
results, followed by prevalent fracture and fracture types and glucocorticoids use.
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OBJECTIVES: To evaluate the efﬁcacy and safety of the centrally acting analgesic, 
tapentadol ER, for the management of moderate to severe osteoarthritis knee pain; 
health status was evaluated using the EuroQol-5 Dimension (EQ-5D) questionnaire. 
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METHODS: Patients received twice-daily doses of tapentadol ER (100–250 mg), 
oxycodone HCl controlled release (CR; 20–50 mg), or placebo over a 15-week treat-
ment period. Patients completed the EQ-5D (evaluates mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression) at baseline and at prespeciﬁed time 
points. RESULTS: Efﬁcacy and safety were evaluated for 1,023 patients who received 
q1 dose of study medication. Overall, the change from baseline in the EQ-5D health 
status index was signiﬁcantly greater with tapentadol ER versus both oxycodone CR 
and placebo (least squares mean difference [95% conﬁdence interval] between tapen-
tadol ER and oxycodone CR, 0.07 [0.03,0.10; P  0.001]; between tapentadol ER 
and placebo, 0.05 [0.02,0.09; P  0.004]). Differences between oxycodone CR and 
placebo were not signiﬁcant (−0.01 [−0.05,0.02; P  0.449]). Across all treatment 
groups at baseline, the percentages of patients reporting no problems in each of 
the EQ-5D dimensions were as follows: mobility, 9%–10%; self-care, 77%–82%; 
usual activities, 14%–17%; pain/discomfort, 0%–1%; and anxiety/depression, 
68%–70%. At endpoint, the percentages of patients reporting no problems 
were mobility: placebo, 16.3%; tapentadol ER, 25.0%; oxycodone CR, 16.7%; 
self-care: placebo, 75.1%; tapentadol ER, 81.1%; oxycodone CR, 80.1%; usual 
activities: placebo, 26.1%; tapentadol ER, 33.7%; oxycodone CR, 27.2%; pain/
discomfort: placebo, 5.6%; tapentadol ER, 9.0%; oxycodone CR 4.7%; and anxiety/
depression: placebo, 71.8%; tapentadol ER, 70.9%; oxycodone CR, 69.6%. A total 
of 61.1%, 75.9%, and 87.4% of patients who received placebo, tapentadol ER, and 
oxycodone CR, respectively, reported q1 treatment-emergent adverse event. CON-
CLUSIONS: Treatment with tapentadol ER (100–250 mg bid) signiﬁcantly improved 
overall health status compared with placebo and oxycodone HCl CR (20–50 mg bid) 
in patients with moderate to severe chronic osteoarthritis knee pain.
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OBJECTIVES: The aim of the current study was to compare the efﬁcacy of pharma-
cological treatments for the management of ﬁbromyalgia with particular focus on 
outcomes considered most important by the Outcome Measures in Rheumatoid 
Arthritis Clinical Trials (OMERACT) symposium. METHODS: A systematic review 
was conducted to identify randomised controlled trials (RCTs) evaluating pharmaco-
logical treatments in adults with ﬁbromyalgia. A Bayesian MTC was performed in 
WinBUGS to estimate the relative efﬁcacy of the evaluated treatments. The primary 
efﬁcacy outcome was the absolute reduction in pain score at study endpoint, based 
on visual analogue or numerical rating scales. Secondary efﬁcacy outcomes included 
proportion of patients responding, changes in Fibromyalgia Impact Questionnaire 
(FIQ) total score, sleep and quality of life measures. Random-effects models were used 
to account for any heterogeneity; ﬁxed-effects models were evaluated in sensitivity 
analysis. RESULTS: Eleven RCTs were included in the review, with 21 RCTs meeting 
criteria for inclusion in the meta-analysis (ﬁxed-dosing regimen, parallel-group study 
design, and high quality [Jadad score q3]). Ten RCTs reported data on the primary 
outcome measure suitable for inclusion in the MTC. These trials evaluated nine treat-
ment regimens: alprazolam, citalopram, duloxetine, ibuprofen, milnacipran, parox-
etine, placebo, pregabalin, ibuprofen  alprazolam. Results from a random-effects 
MTC found that only pregabalin 300, 450, 600 mg/day and duloxetine 20, 60, 
120 mg/day produced signiﬁcantly greater reductions in pain score (p  0.05) than 
placebo. Duloxetine 120 mg/day was signiﬁcantly superior to citalopram 20 mg/day 
and milnacipran 100 mg/day (p  0.05), with no other statistically signiﬁcant differ-
ences reported between active treatments. CONCLUSIONS: Only 21 studies met the 
inclusion criteria for the MTC reﬂecting the relatively poor quality of the majority of 
published studies. Of the treatments included in the MTC of the primary outcome, 
only pregabalin and duloxetine were signiﬁcantly superior to placebo for pain relief.
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OBJECTIVES: Cost-effectiveness models of biologic treatments for RA have been 
shown to be strongly affected by improved physical function, as measured by HAQ-
DI. This analysis was conducted to focus on patients receiving continuous treatment 
with tocilizumab (TCZ) 8 mg/kg monthly and conventional anti-rheumatic medica-
tions for more than 24 weeks, while assessing HAQ-DI scores. METHODS: HAQ-DI 
scores in patients with moderate to severe RA were obtained from the 8-mg/kg treat-
ment groups of three extension studies of four randomised, placebo-controlled studies. 
Analysis focused on observations at or after week 24 to assess the long-term effects 
of treatment. Week 192 was chosen as a cut-off to preserve sufﬁcient sample size. 
Analysis of mean HAQ-DI scores (average at each time window) was conducted for 
all observations. Parallel analysis was conducted separately for patients who received 
previous therapy with anti-TNF agents that did or did not fail. A trendline was ﬁtted 
to the data to describe the overall trend and assess its linearity. In addition, a mixed 
linear model of HAQ-DI as a function of time was estimated at the patient level. 
RESULTS: A total of 1422 patients were available at week 24. Nearly 40% (546) 
have been observed through week 156, and 56 have been observed through week 192. 
All-observed analysis showed a strong linear relationship with a slow, steady decrease 
in HAQ-DI scores through week 192 (week 24  1.05; week 192  0.88; slope  
0.015; R2  0.87). HAQ-DI improvement was monotonic through week 156. Strati-
ﬁcation by previous failure of anti-TNF therapy produced similar ﬁndings. Patient-
level mixed-model results were consistent, showing a signiﬁcant downward slope. 
CONCLUSIONS: Patients with RA treated with 8 mg TCZ in combination with 
standard anti-rheumatic medications have steadily improving HAQ-DI scores while 
on treatment through week 192. Cost-effectiveness models of TCZ should include 
these ﬁndings to accurately gauge the utility of treatment.
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OBJECTIVES: To compare dosing patterns between duloxetine and pregabalin among 
patients with ﬁbromyalgia. METHODS: Using a large US administrative claims data-
base, we examined commercially insured individuals aged 18–64 with ﬁbromyalgia 
who initiated duloxetine or pregabalin in 2006. Initiation was deﬁned as 90-day 
medication gap, with the dispense date of the ﬁrst initiation as the index date. All 
patients included had 12-month continuous enrollment in the pre- and post-index 
period, and at least 30 days supply of duloxetine or pregabalin in the 12 months 
post-index period. Patients with diabetic peripheral neuropathic pain or depression in 
the 12 months pre-index period were excluded. Duloxetine or pregabalin cohorts were 
constructed based on the index agent. Average daily doses of all duloxetine or prega-
balin prescriptions per person, average daily dose in each of the ﬁrst 12 prescriptions, 
and percent of daily dose change from previous prescription were compared between 
duloxetine and pregabalin cohorts. RESULTS: Both the duloxetine (n  3773) and 
pregabalin (n  4189) cohorts had the mean age of 50 years. The duloxetine cohort 
had an average initial daily dose of 55.7 mg, while 161.5 mg for the pregabalin cohort. 
The average daily dose per patient was 55.5 mg for duloxetine and 195.7 mg for pre-
gabalin. The average daily doses for the ﬁrst through twelfth duloxetine scripts varied 
from 55.68 mg (95% Conﬁdence Interval (CI): 54.96, 56.40) to 60.34 mg (95% CI: 
54.71, 65.97), while the numbers were 161.50 mg (95% CI: 159.02, 163.98) and 
282.41 mg (95% CI: 266.89, 297.93) for pregabalin. The percentages of changes in 
daily dose from previous prescriptions were 4.2^1.6% for duloxetine and 1.3^14.3% 
for pregabalin, respectively. CONCLUSIONS: Among patients with ﬁbromyalgia, 
duloxetine and pregabalin initiators had very different dosing patterns. The average 
daily dose for duloxetine was relatively stable over time, while pregabalin patients had 
signiﬁcant dose escalation over the 12-month follow-up period.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyalgia sufferers in Russia          
among the general adult population. METHODS: To The validated Russian version     
of the screening questionnaire was administrated to a representative community 
sample (n  1610), deﬁned by IPSOS® according to the quotas method (sex, age, 
householder’s profession) with a stratiﬁcation according to the region / cities commu-
nity. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyal-
gia. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyalgia.            
A positive screen was deﬁned as: meeting the 4-pain criteria alone (LFESSQ-4), or 
meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). The questionnaire was 
submitted to a sample of rheumatology outpatients (n  399), who were then examined 
by a trained rheumatologist to conﬁrm or exclude the diagnosis of FM according to 
the 1990 American College of Rheumatology criteria. The prevalence of FM in the 
general population was estimated by applying the predictive positive value to eligible 
community subjects (i.e., positive screens). RESULTS: The community sample is con-    
stituted of 885 females and 725 men. 20.1% screened positive for LFESSQ-4 (25.3% 
in females and 13.7% in males respectively). A total of 13.8% screened positive for 
LFESSQ-6 (18.4% in females and 8.1% in males, respectively). Among rheumatology 
outpatients, 43.6% were screened positive for LFESSQ-6 (44.3% in females and 
40.5% in males, respectively), whereas 6.5% were conﬁrmed FM cases (ACR criteria). 
The prevalence of FM was estimated at 2.1% (95% CI: 1.4%–2.8%, 2.8% in females 
and 1.2% in males respectively) in the Russian general population. CONCLUSIONS: 
Our ﬁndings are in agreement with those of earlier national survey reports and previ-
ous publications in US, Canada and Spain. A point prevalence of 2.1 % would trans-
late in approximately 2.5 million of patients with FM in Russia.
PMS9
SECULAR DECREASES IN OSTEOPOROTIC FRACTURE RATES  
1986–2006: A POPULATION-BASED ANALYSIS
Leslie WD1, Morin S2, Azimaee M1, Lix L3, Metge C1, Caetano P1
1University of Manitoba, Winnipeg, MB, Canada, 2McGill University, Montreal, QC, Canada, 
3University of Saskatchewan, Saskatoon, SK, Canada
OBJECTIVES: Secular decreases in hip fracture rates have been reported in some 
countries. Whether this phenomenon applies to other fracture sites has not been 
studied. Our objective was to examine fracture patterns across twenty years in a 
